Tumor treatment system constructed by M1 type macrophage exosome expressing Siglec-10 group

By constructing macrophage exosomes that highly express Siglec-10 group and PD-L1 antibody chimeric, macrophages activate phagocytosis of tumor cells and regulate the tumor microenvironment, the poor effect of tumor immunotherapy in the prior art was solved Problem, effective tumor immunotherapy effect has been achieved.

CN119020416APending Publication Date: 2024-11-26SUN YAT SEN UNIVERSITY SHENZHEN +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411130363.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-16
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing tumor immunotherapy is difficult to effectively activate macrophages to phagocytize tumor cells, and the immunosuppressive mechanism of the tumor microenvironment hinders the attack of the external immune system, resulting in poor tumor treatment effect.

Method used

Construct macrophage exosomes (S10/MExo-aP) with high expression of Siglec-10 and PD-L1 antibody chimeric, and promote macrophage phagocytosis through the interaction between Siglec-10 and CD24 protein on the tumor surface. Tumor cells and block immune checkpoints through PD-L1 antibodies, regulate the tumor microenvironment, increase the ratio of M1 macrophages to M2 macrophages, and activate the immune response.

Benefits of technology

The tumor microenvironment has been improved, the phagocytosis and immune response of macrophages to tumors have been improved, and the efficient tumor immunotherapy effect has been achieved, which has significantly inhibited tumor growth.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020416A_ABST
    Figure CN119020416A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a tumor treatment system constructed by an M1 type macrophage exosome expressing Siglec-10 groups. According to the invention, a S10 / MExo-aP synergistic treatment system is constructed by using a method of biosynthesis (S10 group is expressed in a macrophage exosome) and chemical synthesis (PD-L1 antibody is connected to the macrophage exosome). On one hand, the carried Siglec-10 group can block a channel of tumor CD24 protein and Siglec-10 protein on macrophages, activate the macrophages to remove tumor cells and promote antigen presentation, and further inhibit tumor growth; on the other hand, the connected PD-L1 antibody can regulate and control the tumor microenvironment and reduce the tumor immunosuppression, and all the components cooperate with one another to kill the tumor, so that the efficient tumor immunotherapy effect is cooperatively achieved, and wide application prospects are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a tumor treatment system constructed by M1 macrophage exosomes expressing Siglec-10 groups. Background Art

[0002] Malignant tumors are one of the current problems that need to be solved urgently in clinical medicine. They are a large category of diseases that seriously endanger human life and health and restrict social and economic development. At present, there are three main conventional treatments for malignant tumors in clinical practice, namely surgery, radiotherapy and chemotherapy. Among them, surgical treatment is only for the early stage of solid tumors and is prone to metastasis and recurrence after surgery; radiotherapy is very harmful to the patient's body; chemotherapy methods will also have side effects on the body while killing tumor cells, and tumor cells are prone to drug resistance. With the rapid development of modern molecular biology and immunology, tumor immunotherapy has become a tumor treatment method with great application prospects.

[0003] Tumor immunotherapy mainly activates the patient's own immune system, induces the body to produce an immune response, and then specifically eliminates tumor cells with the antigen. The tumor microenvironment (TME) is an environment that is conducive to tumor growth formed by the interaction between tumor cells and the surrounding stroma. It mainly includes tumor cells themselves and surrounding infiltrating immune cells, stromal cells, fibroblasts, tumor blood vessels, and various chemokines and cytokines. It contains a large number of T cell inhibitory signals such as PD-L1 and CTLA-4, immunosuppressive cells such as regulatory T cells (Treg) and M2 macrophages, and immunosuppressive biological active molecules such as interleukin 10 (IL-10) and tumor growth factor (TGF-β). They build a solid "wall" for the tumor by limiting T cell infiltration and exhausting T cell function to resist the attack of the external immune system, thereby promoting the wild growth of the tumor.

[0004] Among the numerous immune infiltrating cells in the tumor, a relatively important type of cell is tumor-associated macrophages (TAMs), which are involved in almost the entire process of tumor occurrence and development. TAMs in many malignant tumor tissues can account for almost half of the weight of tumor microenvironment cells. TAMs are mainly derived from monocytes that enter the tumor through the blood vessel wall. After being stimulated by the tumor microenvironment, these cells gradually have a unique phenotype and form TAMs. After being activated, the traditional macrophages can be divided into two phenotypes. One is the M1 type, which secretes a large number of cytokines that promote inflammation, participates in the Th1 immune response, can directly phagocytize tumor cells, and inhibits tumor growth; the other is the M2 type, which promotes vascular lymphangiogenesis and wound repair, inhibits tumor immune response, and promotes tumor growth. Specific "don't eat me" signal molecules (such as CD24 and CD47) expressed on the surface of tumor cells, as well as Siglec-10 or Signal regulatory protein-α (SIRPα) highly expressed on the surface of TAM cells, will be recognized as normal cells by TAM cells, inhibiting TAM from phagocytosing tumor cells, thereby escaping phagocytic clearance by macrophages in the tumor microenvironment.

[0005] In summary, the core strategies of tumor immunotherapy can be divided into two main aspects: one is to restore the immune system's ability to recognize and kill tumor cells and enhance the body's anti-tumor immune response; the other is to improve the tumor immunosuppressive microenvironment and destroy the soil that nourishes tumor growth. Therefore, activating tumor-associated macrophages to phagocytize tumor cells, promoting antigen presentation, and regulating the tumor microenvironment to reduce tumor immunosuppression are particularly important for efficient elimination of tumor cells. Summary of the invention

[0006] In order to overcome the shortcomings of the above-mentioned prior art, the present invention proposes a method for constructing a therapeutic system S10 / MExo-aP of dual-chimeric macrophage exosomes (MExo) that highly express Siglec-10 groups (S10) and are connected to PD-L1 antibodies (aP). The constructed S10 / MExo-aP system can utilize the inhibitory effect of Siglec-10 groups (S10) on tumors and the regulatory effect of PD-L1 antibodies (aP) on tumor microenvironment, thereby synergistically achieving efficient tumor immunotherapy effects.

[0007] In order to achieve the above object, the technical solution adopted by the present invention is:

[0008] The first aspect of the present invention provides a method for constructing a therapeutic system S10 / MExo-aP of a dual chimeric macrophage exosome (MExo) that highly expresses a Siglec-10 group (S10) and is linked to a PD-L1 antibody (aP), the method comprising the following steps:

[0009] S1. Add lentiviral particles carrying the Siglec-10 gene to a suspension containing RAW 264.7 cells, and culture in an incubator at 37°C and 5% CO2 for 5-7 days to obtain RAW 264.7 macrophages expressing the Siglec-10 gene;

[0010] S2. The supernatant of RAW 264.7 macrophages expressing Siglec-10 group was collected by centrifugation. The supernatant was collected and precipitated by ultracentrifugation to obtain the exosomes S10 / Mexo of RAW 264.7 macrophages expressing Siglec-10 group.

[0011] S3, synthesizing an MMP enzyme-sensitive peptide RVGLP with an active carboxyl group (NHS) at one end and 6-maleimide (6-Mal) at the other end, and then connecting the peptide to the PD-L1 antibody (aP) through the reaction between the active carboxyl group NHS of the peptide and the amino group of the PD-L1 antibody to obtain aP-RVGLP;

[0012] S4. Tri(2-carboxyethyl)phosphine was co-incubated with S10 / MExo, and TECP was used to open the disulfide bonds of the surface membrane proteins of S10 / MExo to expose the thiol groups. The thiol-exposed S10 / MExo was then co-incubated with aP-RVGLP to connect the exposed thiol groups on the surface of S10 / MExo to the 6-Mal end of aP-RVGLP, thus constructing a dual-chimeric S10 / MExo-aP system.

[0013] The present invention uses the methods of biosynthesis (S10 group is expressed into macrophage exosomes) and chemical synthesis (PD-L1 antibody is connected to macrophage exosomes) to construct a S10 / MExo-aP synergistic treatment system. Its particle size is about 100nm, which can accumulate at the tumor site, and under the action of MMP enzymes in the tumor microenvironment, sensitively release S10 / MExo and PD-L1 antibodies, thereby exerting the following effects: ① The released S10 / MExo can increase the ratio of M1 macrophages to M2 macrophages in the tumor microenvironment; ② The Siglec-10 group of S10 / MExo can interact with the CD24 protein on the surface of the tumor, promote macrophage phagocytosis and tumor clearance; ③ Promote antigen presentation and activate immunity; ④ PD-L1 antibody interacts with PD-L1 protein on the surface of tumor cells, blocks immune checkpoints, reduces immunosuppression, and regulates the tumor microenvironment. Therefore, the S10 / MExo-aP system constructed by the present invention, each component synergizes immune killing tumors, thereby achieving efficient tumor treatment effects.

[0014] Preferably, in S1, the plasmid expressing the Siglec-10 gene is infected into HEK-293T cells by liposome transfection to obtain lentiviral particles carrying the Siglec-10 gene.

[0015] Preferably, the method for collecting the supernatant in S2 is: first centrifuge at 200-400g for 7-15 minutes to remove cells, then centrifuge the obtained culture medium at 1500-3000g for 7-15 minutes to remove cell debris, and then centrifuge the obtained supernatant at 9000-12000g for 20-40 minutes to remove small cell debris, thereby obtaining the supernatant.

[0016] Preferably, the ultracentrifugation in S2 is 90000-120000 g for 1-3 hours.

[0017] Preferably, S3 connects the peptide to the PD-L1 antibody in a PBS solution, and the molar ratio of the RVGLP peptide to the PD-L1 antibody is 45-55:1.

[0018] Preferably, S3 is performed in a 4°C refrigerator to connect the peptide to the PD-L1 antibody, and reacts at a speed of 700-1500 rpm / hour for 10-15 hours.

[0019] Preferably, in S4, the temperature for incubating tri(2-carboxyethyl)phosphine and S10 / MExo is 40-37° C. and the time is 20-40 min.

[0020] Preferably, in S4, the temperature for incubating S10 / MExo and aP-RVGLP is 20-28° C. and the time is 0.5-1.5 h.

[0021] Preferably, in S4, the usage ratio of tri(2-carboxyethyl)phosphine to S10 / MExo is 0.8-1.2 mM:100 μg; and the mass ratio of S10 / MExo to aP-RVGLP is 4-6:1.

[0022] The second aspect of the present invention provides a therapeutic system S10 / MExo-aP prepared by the construction method described in the first aspect.

[0023] The third aspect of the present invention provides the use of the therapeutic system S10 / MExo-aP described in the second aspect in the preparation of a tumor immunotherapy preparation.

[0024] The therapeutic system S10 / MExo-aP constructed by the method of the present invention can utilize the inhibitory effect of the Siglec-10 group (S10) on tumors and the regulatory effect of the PD-L1 antibody (aP) on the tumor microenvironment, thereby synergistically achieving an efficient tumor immunotherapy effect.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The present invention discloses a method for constructing a tumor immunotherapy system (S10 / MExo-aP) of macrophage exosomes (MExo) that highly express Siglec-10 groups (S10) and are connected to PD-L1 antibodies (aP). First, the Siglec-10 (S10) gene is transfected into RAW 264.7 cells by lentiviral particles to obtain macrophages (S10 / M) that highly express Siglec-10 groups, then S10 / M macrophage exosomes are extracted, and the Singlec-10 group is embedded in the macrophage exosomes to obtain S10 / MExo. Secondly, the PD-L1 antibody was coupled to a peptide (Arg-Val-Gly-Leu-Pro, RVGLP) that can be broken under the sensitivity of MMP enzymes in the tumor microenvironment through amino-carboxyl chemical coupling; the two ends of the peptide were activated carboxyl (NHS) and maleimide (6-maleimide, 6-Mal), and the activated carboxyl end could react with the amino group of the PD-L1 antibody. The peptide was connected to the PD-L1 antibody, and the 6-Mal end could interact with the sulfhydryl group on the surface of S10-Exo / M with open disulfide bonds, so that the PD-L1 antibody was chimeric on S10 / MExo through chemical coupling, thereby obtaining the S10 / MExo-aP dual-chimeric tumor synergistic immunotherapy system. On the one hand, the carried Siglec-10 group can block the pathway between tumor CD24 protein and Siglec-10 protein on macrophages, activate macrophages to clear tumor cells, promote antigen presentation, and inhibit tumor growth; on the other hand, the connected PD-L1 antibody can regulate the tumor microenvironment, reduce tumor immunosuppression, and thus synergistically achieve efficient tumor immunotherapy effects. Therefore, the S10 / MExo-aP system constructed by the present invention, each component synergistically kills tumors, thereby achieving efficient tumor treatment effects, and has broad application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 YOE-LV005-mSiglecg-mCherry lentiviral plasmid was constructed;

[0028] Figure 2 Successfully expressed Siglec-10 protein in 1293T cells and packaged Siglec-10 lentivirus;

[0029] Figure 3 Macrophages highly express Siglec-10;

[0030] Figure 4 It is a macrophage exosome carrying Siglec-10 group;

[0031] Figure 5 is the particle size potential distribution of macrophage exosomes carrying Siglec-10 groups;

[0032] Figure 6 This is the fluorescence imaging of S10 / MExo-aP under laser confocal microscope;

[0033] Figure 7 For S10 / MExo-aP, the ratio of M1 macrophages to M2 macrophages is increased;

[0034] Figure 8 S10-Exo / M-aP can inhibit the growth of orthotopic tumors in tumor-bearing mice. DETAILED DESCRIPTION

[0035] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in each embodiment of the present invention described below can be combined with each other as long as they do not conflict with each other.

[0036] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0037] Example: Construction of a therapeutic system S10 / MExo-aP of a dual chimeric macrophage exosome (MExo) that highly expresses Siglec-10 group (S10) and is linked to PD-L1 antibody (aP)

[0038] The construction method specifically includes the following steps:

[0039] (1) Construction of Siglec-10 gene lentiviral particles

[0040] The plasmid expressing Siglec-10 gene (YOE-LV005-mSiglecg-mCherry lentiviral plasmid) was customized from Guangzhou Yuanjing Biotechnology Co., Ltd., and its plasmid map is shown in Figure 1As shown, the sequence number of Siglec-10 gene in NCBI is NM_172900.3). 1 μg of plasmid expressing Siglec-10 gene was dissolved in 250 μL Opti-MEM and mixed thoroughly, then 2 μL LipoFectamin 2000 was added to the solution, mixed thoroughly again, and reacted at room temperature for 30 minutes; then the reacted system was added to the culture medium (DMEM complete medium containing 10% serum) containing HEK-293T cells (purchased from Peking Union Medical College), and the number ratio of cells to target plasmid was 1:3. After culture, HEK-293T cells were successfully packaged to obtain lentivirus. The culture conditions are as follows: culture in an incubator at 37°C and 5% CO2. After 24 hours, the supernatant was collected, centrifuged at 500g for 10 minutes, and then passed through a 0.45μm filter to remove cell impurities; the virus purification reagent Lenti Concentration Solution was added and resuspended in a 50mL centrifuge tube, incubated at 4°C for 8 hours, centrifuged at 3500g for 25 minutes at 4°C, the supernatant was removed, and the cells were resuspended in a sterile PBS solution.

[0041] (2) Obtaining macrophages expressing Siglec-10 gene

[0042] The suspension containing RAW 264.7 cells was plated in a T25 cell culture flask (5×10 6 cells), the culture medium is a DMEM complete medium containing 10% FBS, placed in a 37°C, 5% CO2 incubator for culture, and the lentiviral particles with Siglec-10 gene obtained in step (1) (MOI=10) are added to the culture system. After culturing for 24 hours, the new culture medium is replaced and cultured for 48 hours; then the culture medium containing puromycin (1-3 μg / mL) is replaced for 24 hours to screen macrophages transferred with Siglec-10 gene; finally, the DMEM complete medium without exosome serum is replaced and cultured for 48 hours. This culture system is ready for use.

[0043] like Figure 2 As shown, red fluorescence can be observed under a fluorescence microscope, indicating that HEK-293T cells successfully expressed Siglec-10 protein and successfully packaged Siglec-10 lentivirus. The collected lentivirus was infected into macrophages, and red fluorescence was observed under a fluorescence microscope, indicating that Siglec-10 macrophage S10 / M has been successfully constructed, and it can be observed that about 60-70% of the cells highly express Siglec-10. Red fluorescence can be observed on the cell membrane by confocal microscopy, further proving that Siglec-10 protein is successfully highly expressed in macrophages ( Figure 3 ).

[0044] (3) Obtaining macrophage exosomes with chimeric Siglec-10 groups

[0045] The macrophage culture fluid expressing the Siglec-10 group in step (2) was collected and centrifuged at 300g for 10 minutes to remove the cells. The obtained culture fluid was centrifuged at 2000g for 10 minutes to remove cell debris, and the obtained supernatant was further centrifuged (10000g, 30 minutes) to remove small cell debris; the supernatant was further centrifuged (100000g ultracentrifugation for 2 hours), and the obtained precipitate was resuspended with PBS buffer to obtain macrophage exosomes S10 / Mexo expressing the Siglec-10 group, and the protein concentration was determined by BCA protein kit, and its concentration was quantified as 1 mg / mL, and stored for later use.

[0046] Extraction of macrophage exosomes carrying Siglec-10 groups ( Figure 4 ), and its particle size potential distribution is as follows Figure 5 As shown, it indicates that the particle size is mainly distributed around 100 nm.

[0047] (4) PD-L1 antibody linked to MMP enzyme-sensitive peptide

[0048] A MMP enzyme-sensitive peptide (Arg-Val-Gly-Leu-Pro, RVGLP) linker with an active carboxyl group (NHS) at one end and 6-maleimide (6-Mal) at the other end was custom-synthesized from Suzhou Qiangyao Biotechnology Co., Ltd. The RVGLP peptide (0.25 mg / mL) and the PD-L1 antibody were mixed in 5 mL of PBS solution (the molar ratio of the RVGLP peptide to the PD-L1 antibody was 50:1), and then the mixed solution was placed in a vertical suspension instrument and placed in a 4°C refrigerator to react at a speed of 1000 rpm / hour for 12 hours; after the reaction, the product was placed in a 10 kDa ultrafiltration tube, centrifuged at 7000 rpm for 40 minutes, and the resulting precipitate was added to PBS and resuspended. After centrifugation at 7000 rpm for 30 minutes, the precipitate was resuspended in PBS for use, and the chimeric PD-L1 antibody (aP-RVGLP) was obtained. The principle of this reaction process is that the active carboxyl NHS of RVGLP reacts with the amino group of the PD-L1 antibody (aP) to connect the peptide segment to the PD-L1 antibody, thereby obtaining aP-RVGLP.

[0049] (5) Obtaining macrophage exosomes expressing chimeric PD-L1 antibody (aP-RVGLP) and Siglec-10 group

[0050] 1mM Tris(2-carboxyethyl)phosphine (TECP) was co-incubated with 100μg S10 / MExo at 37°C for 30min. Under the action of TECP, the disulfide bonds of the surface membrane proteins of S10 / MExo were opened, exposing the thiol groups. Then, the thiol-exposed S10 / MExo was co-incubated with aP-RVGLP at 25°C for 1h (mass ratio of 5:1). At this time, the thiol groups exposed on the surface of S10 / MExo could be connected to the 6-Mal end of aP-RVGLP, thereby constructing a dual-chimeric S10 / MExo-aP tumor synergistic treatment system.

[0051] The constructed S10-Exo / M-aP was stained with fluorescent secondary antibody (green), and fluorescence imaging by laser confocal microscopy showed that the red S10-Exo and the green fluorescent PD-L1 antibody co-localized (yellow), indicating that S10-Exo / M had successfully linked to the PD-L1 antibody ( Figure 6 ). This indicates that the MMP sensitive peptide (Arg-Val-Gly-Leu-Pro, RVGLP) has been connected to the PD-L1 antibody and to the surface of S10-Exo / M (S10-Exo was previously stained with DIO dye, red), and S10-Exo / M-aP was successfully constructed.

[0052] Experimental example: Verification of the immunotherapy effect of the therapeutic system S10 / MExo-aP on tumors

[0053] (1) S10 / MExo-aP acts on the tumor microenvironment

[0054] S10-Exo / M1-aP was administered via the tail vein of 4T1 tumor-bearing mice at a dose of 100 μg every other day. After three doses, the tumors were harvested to detect the ratio of tumor-associated macrophages M1 to M2 in the tumor microenvironment. Figure 7 As shown, S10-Exo / M-aP can increase the ratio of M1 macrophages to M2 macrophages, indicating that S10-Exo / M-aP can activate the immune response and has the ability to reduce immunosuppression and regulate the tumor microenvironment.

[0055] (2) S10-Exo / M1-aP inhibits the growth of orthotopic tumors in tumor-bearing mice

[0056] S10-Exo / M1-aP was administered via the tail vein of tumor-bearing mice at a dose of 100 μg every other day. The tumor size was measured daily. When the tumor volume exceeded 1000 mm 3 After euthanasia, the changes in tumor volume were counted for 30 days. Figure 8As shown, S10-Exo / M-aP can cooperate with macrophages to phagocytose tumors, activate immunity and reduce tumor immunity, thereby inhibiting tumor growth.

[0057] In summary, the tumor immunotherapy system constructed based on macrophage exosomes (MExo) of the present invention, on the one hand, carries the Siglec-10 group (S10), blocks the pathway between tumor CD24 protein and Siglec-10 protein on macrophages, activates macrophages to clear tumor cells, promotes antigen presentation, and thereby inhibits tumor growth; on the other hand, it carries the PD-L1 antibody (aP), regulates the tumor microenvironment, reduces tumor immunosuppression, and thereby synergistically achieves efficient tumor immunotherapy effects.

[0058] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. For those skilled in the art, various changes, modifications, substitutions and variations of these embodiments are made without departing from the principles and spirit of the present invention, and still fall within the protection scope of the present invention.

Claims

1. A method for constructing a dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is linked to PD-L1 antibodies, characterized in that: The following steps are involved: S1. Add lentiviral particles carrying the Siglec-10 gene to a suspension containing RAW 264.7 cells, and culture in an incubator at 37°C and 5% CO2 for 5-7 days to obtain RAW 264.7 macrophages expressing the Siglec-10 gene; S2. The supernatant of RAW 264.7 macrophages expressing Siglec-10 group was collected by centrifugation. The supernatant was collected and precipitated by ultracentrifugation to obtain the exosomes S10 / Mexo of RAW 264.7 macrophages expressing Siglec-10 group. S3, synthesizing the MMP enzyme-sensitive peptide RVGLP with an active carboxyl group at one end and a 6-maleimide at the other end, and then connecting the peptide to the PD-L1 antibody through the reaction of the active carboxyl group NHS of the peptide with the amino group of the PD-L1 antibody to obtain aP-RVGLP; S4. Tri(2-carboxyethyl)phosphine was co-incubated with S10 / MExo, and TECP was used to open the disulfide bonds of the surface membrane proteins of S10 / MExo to expose the thiol groups. The thiol-exposed S10 / MExo was then co-incubated with aP-RVGLP to connect the exposed thiol groups on the surface of S10 / MExo to the 6-Mal end of aP-RVGLP, thus constructing a dual-chimeric S10 / MExo-aP system.

2. The method for constructing the dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: In S1, the plasmid expressing the Siglec-10 gene was infected into HEK-293T cells by liposome transfection to obtain lentiviral particles carrying the Siglec-10 gene.

3. The method for constructing the dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: The method for collecting the supernatant of S2 is: first centrifuge at 200-400g for 7-15 minutes to remove cells, then centrifuge the obtained culture medium at 1500-3000g for 7-15 minutes to remove cell debris, and then centrifuge the obtained supernatant at 9000-12000g for 20-40 minutes to remove small cell debris to obtain the supernatant; the ultracentrifugation described in S2 is ultracentrifugation at 90000-120000g for 1-3 hours.

4. The method for constructing the dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: S3 connected the peptide to the PD-L1 antibody in PBS solution, and the molar ratio of RVGLP peptide to PD-L1 antibody was 45-55:

1.

5. The method for constructing the dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: S3 connects the peptide to the PD-L1 antibody in a 4°C refrigerator and reacts at a speed of 700-1500 rpm / hour for 10-15 hours.

6. The method for constructing the dual-chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: In S4, the tri(2-carboxyethyl)phosphine and S10 / MExo are co-incubated at a temperature of 40-37° C. for 20-40 min.

7. The method for constructing the dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: In S4, the temperature for incubation of S10 / MExo and aP-RVGLP was 20-28°C for 0.5-1.5 h.

8. The method for constructing the dual chimeric macrophage exosome therapeutic system S10 / MExo-aP that highly expresses Siglec-10 groups and is connected to PD-L1 antibodies according to claim 1, characterized in that: In S4, the usage ratio of tri(2-carboxyethyl)phosphine to S10 / MExo is 0.8-1.2 mM:100 μg; the mass ratio of S10 / MExo to aP-RVGLP is 4-6:

1.

9. The therapeutic system S10 / MExo-aP prepared by the construction method according to any one of claims 1 to 8.

10. Use of the therapeutic system S10 / MExo-aP according to claim 9 in the preparation of tumor immunotherapy preparations.

Citation Information

Patent Citations

  • Targeted synergistic drug system based on Treg cell exosome and preparation method thereof

    CN114099664A

  • Macrophage-based derived exosome and injectable gel

    CN115572711A

  • Exosome-based antitumor vaccine

    US20210324342A1